We also found other Philadelphia chromosome -negative MPN (Ph-MPN) patients (hydroxyurea- and ruxolitinib-naïve ET and MF patients) had significantly increased IGF-1R relative to controls (Fig 3). Here, IGF1R is linked to myeloproliferative neoplasm.